Jazz Pharmaceuticals, Inc.
Corporate Headquarters Fourth Floor, Connaugh
One Burlington Road
About Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals plc is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. We have a diverse portfolio of products and product candidates, with a focus in the areas of sleep and hematology/oncology. We also support commercial products in therapeutic areas where we can meaningfully address serious medical needs.
As part of our unwavering commitment to improve patients’ lives, we continue to expand our commercial product portfolio and our research and development pipeline in therapeutic areas that can leverage our unique expertise. We do this through a growth strategy of growing sales of the existing products in our portfolio; acquiring additional differentiated products that are on the market or product candidates that are in late-stage development; and pursuing focused development of a pipeline of post-discovery differentiated product candidates.
We have a strong patient-focused culture at Jazz Pharmaceuticals that our employees believe in and pursue every day. It is clearly identified through our mission, vision and core values. Each member of our team makes integral contributions and is working toward a common goal to improve patients' lives. Everything we do at Jazz Pharmaceuticals is focused on three things:
• Putting patients first
• Being a great place to work
• Living our core values — integrity, collaboration, passion, pursuit of excellence and innovation
345 articles with Jazz Pharmaceuticals, Inc.
Although August is a busy month on the U.S. Food and Drug Administration (FDA)’s calendar for PDUFA dates, this week’s dates were almost all approved ahead of schedule. Here’s a look.
The U.S. Food and Drug Administration (FDA) approved Xywav, the first new treatment option indicated for both cataplexy and excessive daytime sleepiness in people living with narcolepsy in more than 15 years.
Wrapping up the month of July, there are three PDUFA dates on the U.S. Food and Drug Administration (FDA) calendar.
The approval was based on monotherapy clinical data from a trial in 105 adults with SCLC whose disease progressed after platinum-based chemotherapy.
5/15/2020Pharma, biotech and life sciences companies bolster their executive teams and boards with these Movers & Shakers.
The following is a roundup of some of this week's non-coronavirus biopharma news.
The U.S. Food and Drug Administration accepted the companies’ New Drug Application for lurbinectedin under Priority Review.
1/23/2020Companies from across the globe provide updates on their businesses and pipelines.
Even with the holiday week, there was still some clinical trial news coming out. Here’s a look.
An investigational medicine in late-stage development by Jazz Pharmaceuticals hit the mark in treating cataplexy and excessive daytime sleepiness in adults with narcolepsy.
Jazz Pharmaceuticals plc announced that the U.S. Drug Enforcement Agency has designated solriamfetol, also known as Sunosi, as a Schedule IV medicine.
Jazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development
Jazz Pharmaceuticals plc announced the appointment of Robert Iannone, M.D., M.S.C.E., as executive vice president, research and development, effective May 29, 2019.
Data to be presented underscore commitment to developing life-changing medicines in hematology/oncology for people with limited or no treatment options
Received FDA Approval of Sunosi for Excessive Daytime Sleepiness (EDS) Associated with Narcolepsy or Obstructive Sleep Apnea (OSA)
Jazz Pharmaceuticals plc announced that the company will be webcasting its corporate presentations at two upcoming investor conferences.
Jazz Pharmaceuticals plc announced that it will report its 2019 first quarter financial results on Tuesday, May 7, 2019, after the close of the financial markets.
The government charged the three companies with using charitable foundations they financially supported to finance copays of Medicare and Medicaid patients, which is a violation of law.
Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness
JZP-258 achieves primary and key secondary endpoints demonstrating highly statistically significant differences in weekly number of cataplexy attacks and Epworth Sleepiness Scale scores compared to placebo
Shares of Jazz Pharmaceuticals are climbing in premarket trading following a late Wednesday announcement that the U.S. Food and Drug Administration granted approval for Sunosi, a treatment for people with narcolepsy.
Jazz Pharmaceuticals Announces U.S. FDA Approval of Sunosi™ (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor approved by the FDA to improve wakefulness in adults living with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea